



DZHK
DEUTSCHES ZENTRUM FÜR
HERZ-KREISLAUF-FORSCHUNG E.V.

UniversitätsKlinikum Heidelberg

External Seminar Speaker

Dr. Bert Klebl

Lead Discovery Center Dortmund (LDC)
Managing Director and Chief Scientific Officer



Place: Analysezentrum 3, 2. OG, Room 02.332

Date: Tuesday, April 2nd

Time: 12.00 am

Connecting Academia and Venture Capital and/or Pharmaceutical Industry

The Lead Discovery Center GmbH (LDC) founded in 2008 by Max Planck Innovation GmbH and the Max Planck Society, transforms results from basic research into novel drug candidates. LDC closely collaborates with basic researchers from Max Planck and elsewhere to leverage excellent biomedical basic research. LDC's academic network represents thousands of scientists and a large pipeline of novel ideas for treating diseases with unmet medical need. Therefore, LDC is a translational incubator for academic project ideas. LDC has established a flexible, but industry-type drug discovery infrastructure. LDC's current portfolio contains ~20 highly innovative and collaborative drug discovery projects based on different treatment modalities. LDC tries to transform these innovative early-stage projects into attractive licensing opportunities and has built up an excellent track record in partnering projects to industries, like Bayer AG, Boehringer Ingelheim, Merck KGaA, Quriel, RaND, Grünenthal etc. Recently, LDC has supported three novel start-ups in exchange for equity and licenses, ReWind Therapeutics, Leuven/Belgium, Quench Bio Inc., Cambridge/USA and a Dortmund-based oncology spin-off.

I will present the LDC "incubator" concept and successful case studies of academic scientific hypotheses being translated into drug candidates.

Host: **Prof. Dr. med. Johannes Backs**

Director of the Department Molecular Cardiology and Epigenetics
Department of Internal Medicine VIII
University of Heidelberg